Sotyktu vs Otezla
A side-by-side look at two autoimmune medications advertised on TV. Informational only — not medical advice.
| US Sotyktu | US Otezla | |
|---|---|---|
| Generic name | deucravacitinib | apremilast |
| Drug class | TYK2 Inhibitor | PDE4 Inhibitor |
| Treats | Plaque psoriasis | Plaque psoriasis, psoriatic arthritis, Behçet's disease |
| Category | Autoimmune | Autoimmune |
| Manufacturer | Bristol-Myers Squibb | Amgen |
| Year approved | 2022 | 2014 |
| FDA warning | Moderate warnings | No boxed warning |
| Est. TV ad spend | $130M | $110M |
| Common side effects | Common cold symptoms, Increased infections, Cold sores, Mouth sores | Diarrhea, Nausea, Headache, Weight loss |
Frequently asked questions
Is Sotyktu or Otezla better?
Neither is universally "better." Sotyktu (deucravacitinib) and Otezla (apremilast) are both used for autoimmune, but the right choice depends on your medical history, insurance and your doctor's guidance. This comparison is informational only.
What's the difference between Sotyktu and Otezla?
Sotyktu is a TYK2 Inhibitor made by Bristol-Myers Squibb, while Otezla is a PDE4 Inhibitor made by Amgen. See the table above for a side-by-side breakdown.
Which one spends more on TV ads?
Sotyktu has the larger estimated TV advertising budget of the two.